Renseignements informations Cebiphar
CEBIPHAR updates

Particle Contamination Challenges – USP 788 : Are you ready for the chapter becoming official on August 1, 2026 ?

07/04/2026

Share:

📃 The USP <788> chapter “Particulate Matter in Injections” is evolving and will become officially applicable on August 1, 2026.

Following updates published in July 2025, this chapter introduces important clarifications and progressive changes (USP-PF).

🎯 A key challenge : adapting analytical methods to complex matrices

One of the main challenges of this regulatory evolution is improving the management of particle analysis, particularly in complex matrices.

🔍 Focus on oily suspensions

These types of matrices may create significant analytical constraints, including :

These parameters can make Method 1 (Light Obscuration) unsuitable. In such situations, Method 2 (Microscopy) may become necessary, provided its use is supported by a robust and well-documented scientific rationale.

⚙️ Anticipating USP <788> requirements : a structured approach

To effectively address these new expectations, it is essential to :

This approach helps anticipate regulatory constraints while ensuring reliable results.

🤝 At CEBIPHAR, we provide :

Anticipating these expectations is now essential to secure your development and control strategies.

📩 Our teams are available to discuss your challenges and projects, contact us !

Other news

CEBIPHAR updates

ICH Q3E : How the...

📃 ICH Q3E is set to reshape how Extractables & Leachables (E&L) studies are designed and controlled. Released as a draft in August 2025,...
Read the article
CEBIPHAR updates

Nitrosamines : no one-size-fits-all method....

📃 Since 2019, the regulatory framework on nitrosamines in pharmaceutical products has kept evolving. Systematic risk evaluation, confirmatory testing, marketing authorization variations, lifecycle management...
Read the article
CEBIPHAR updates

Injectable Hyaluronic Acid : Overcome...

📃 Hyaluronic acid has established itself as a key segment of the injectable medical device market, in both aesthetic medicine and orthopaedics. Driven by...
Read the article
Nous pouvons vous accompagner dans le développement et le contrôle de vos produits
Contact Nous pouvons vous accompagner dans le développement et le contrôle de vos produits Discuter avec l'un de nos scientifiques
STAY TUNED

The main objective of our Newsletter is to focus on one of our services by showing the added value it can bring you.

Newsletter Fr